UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer

Loading news article.

UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer | WAPE

UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer

Article summary

Related companies

Comments —